학술논문
Safety, Tolerability And Ldl-C Reduction With A Novel Anti-Pcsk9 Recombinant Fusion Protein (Lib003): Results Of A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study
Document Type
Abstract
Author
Source
In Atherosclerosis August 2019 287:e7-e7
Subject
Language
ISSN
0021-9150